title: PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.
abstract: BACKGROUND Regulated upon activation, normal T cells expressed and secreted (RANTES) is associated with inflammation and atherosclerosis. We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, on RANTES in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia. MATERIAL AND METHODS This study evaluated cross-sectional and interventional studies of 25 T2DM patients with hypertriglyceridemia (group A) and 32 controls (group B). Group A was treated with fenofibrate (200 mg/day) for 8 weeks. Serum RANTES and clinical characteristics were examined. RESULTS Serum RANTES was significantly higher in group A compared with group B (59.04±16.74 vs. 38.57±12.98 ng/ml, P<0.001) and correlated with triglycerides (TG) (r=0.535, P<0.001), fasting blood glucose (FBG) (r=0.485, P<0.001), glycosylated hemoglobin (HbA1c) (r=0.485, P<0.001), homocysteine (Hcy) (r=0.520, P<0.001), and high-sensitivity C-reactive protein (hsCRP) (r=0.701, P<0.001). In multiple regression analysis after controlling for confounders, increased hsCRP levels (β=7.430, P<0.001) and T2DM with hypertriglyceridemia (β=11.496, P=0.002) were independently related to high serum RANTES levels. After 8 weeks of fenofibrate treatment, serum RANTES significantly decreased in group A compared with baseline (52.75±17.41 vs. 59.04±16.74 ng/ml, P=0.018). CONCLUSIONS Fenofibrate decreased serum RANTES levels in T2DM patients with hypertriglyceridemia, indicating that PPAR-a agonists may play an important role in inhibiting inflammatory responses.
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
authors.forename: Xiaomeng
authors.initials: X
authors.lastname: Feng
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
authors.forename: Xia
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
authors.forename: Yumei
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
authors.forename: Heng
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
authors.forename: Yuan
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
authors.forename: Guang
authors.initials: G
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D018946:Chemokine CCL5 / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047493:PPAR alpha / Q000819:agonists*; D012044:Regression Analysis
chemical_list: D018946:Chemokine CCL5; D047493:PPAR alpha; D011345:Fenofibrate